PBYI
Price
$9.77
Change
-$0.05 (-0.51%)
Updated
Sep 25 closing price
Capitalization
506.91M
33 days until earnings call
Intraday BUY SELL Signals
RYTM
Price
$98.66
Change
+$0.35 (+0.36%)
Updated
Sep 25 closing price
Capitalization
6.77B
45 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PBYI vs RYTM

PBYI vs RYTM Comparison Chart in %
View a ticker or compare two or three
VS
PBYI vs. RYTM commentary
Sep 26, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBYI is a Buy and RYTM is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
PBYI vs RYTM: Fundamental Ratings
PBYI
RYTM
OUTLOOK RATING
1..100
3215
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
80
Overvalued
PROFIT vs RISK RATING
1..100
7619
SMR RATING
1..100
44100
PRICE GROWTH RATING
1..100
3657
P/E GROWTH RATING
1..100
3100
SEASONALITY SCORE
1..100
3650

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PBYI's Valuation (75) in the Biotechnology industry is in the same range as RYTM (80). This means that PBYI’s stock grew similarly to RYTM’s over the last 12 months.

RYTM's Profit vs Risk Rating (19) in the Biotechnology industry is somewhat better than the same rating for PBYI (76). This means that RYTM’s stock grew somewhat faster than PBYI’s over the last 12 months.

PBYI's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for RYTM (100). This means that PBYI’s stock grew somewhat faster than RYTM’s over the last 12 months.

PBYI's Price Growth Rating (36) in the Biotechnology industry is in the same range as RYTM (57). This means that PBYI’s stock grew similarly to RYTM’s over the last 12 months.

PBYI's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for RYTM (100). This means that PBYI’s stock grew significantly faster than RYTM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PBYIRYTM
RSI
ODDS (%)
Bearish Trend 5 days ago
74%
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 5 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 9 days ago
89%
Bullish Trend 1 day ago
81%
Declines
ODDS (%)
Bearish Trend 18 days ago
80%
Bearish Trend 12 days ago
73%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
89%
COMPARISON
Comparison
Sep 26, 2026
Stock price -- (PBYI: $9.77 vs. RYTM: $98.66)
Brand notoriety: PBYI and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PBYI: 93% vs. RYTM: 170%
Market capitalization -- PBYI: $506.91M vs. RYTM: $6.77B
PBYI [@Biotechnology] is valued at $506.91M. RYTM’s [@Biotechnology] market capitalization is $6.77B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.4B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PBYI’s FA Score shows that 1 FA rating(s) are green while RYTM’s FA Score has 1 green FA rating(s).

  • PBYI’s FA Score: 1 green, 4 red.
  • RYTM’s FA Score: 1 green, 4 red.
According to our system of comparison, PBYI is a better buy in the long-term than RYTM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PBYI’s TA Score shows that 4 TA indicator(s) are bullish while RYTM’s TA Score has 4 bullish TA indicator(s).

  • PBYI’s TA Score: 4 bullish, 4 bearish.
  • RYTM’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, PBYI is a better buy in the short-term than RYTM.

Price Growth

PBYI (@Biotechnology) experienced а +1.77% price change this week, while RYTM (@Biotechnology) price change was +0.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.17%. For the same industry, the average monthly price growth was -13.24%, and the average quarterly price growth was +5.35%.

Reported Earning Dates

PBYI is expected to report earnings on Oct 29, 2026.

RYTM is expected to report earnings on Nov 10, 2026.

Industries' Descriptions

@Biotechnology (-4.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
PBYI
Daily Signal:
Gain/Loss:
RYTM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
UDOW66.361.72
+2.66%
ProShares UltraPro Dow30 (UDOW)
MTUM318.501.05
+0.33%
iShares MSCI USA Momentum Factor ETF (MTUM)
BUFX22.680.04
+0.15%
FT Vest Laddered Enhance & Moderate Buffer ETF (BUFX)
ORCX18.38-0.70
-3.67%
Defiance Daily Target 2X Long ORCL ETF (ORCX)
CRWL95.34-5.79
-5.72%
GraniteShares 2x Long CRWD Daily ETF (CRWL)

RYTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with SRRK. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then SRRK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYTM
1D Price
Change %
RYTM100%
+0.36%
SRRK - RYTM
44%
Loosely correlated
+0.04%
VIR - RYTM
43%
Loosely correlated
-0.56%
PCVX - RYTM
40%
Loosely correlated
-1.21%
JBIO - RYTM
39%
Loosely correlated
-2.10%
GMAB - RYTM
39%
Loosely correlated
+1.41%
More